Jason Hearn

Jason Hearn, MD

Assistant Professor

UH B2C490
1500 E Medical Center Dr
Ann Arbor, MI 48109

734-936-4300

Clinical Contacts

734-936-4300

Administrative Contact

Humera Niazi 734-647-9956

Biography

Dr. Hearn is an Assistant Professor in the Department of Radiation Oncology at the University of Michigan. He completed his medical training at Harvard Medical School and his residency in radiation oncology at Cleveland Clinic. Dr. Hearn investigates mechanisms by which prostate cancer may become resistant to current treatments.

Dr. Hearn also treats bladder cancer and has been impressed by the promising responses (sometimes dramatic and long-lasting) that some patients with bladder cancer have when treated with immunotherapy to harness the body’s immune system. Dr. Hearn is currently enrolling patients with muscle-invasive bladder cancer into a clinical trial investigating the addition of immunotherapy to conventional bladder preservation therapy (radiation therapy + chemotherapy) to potentially improve the chance that a patient can be both cured and keep his or her bladder.  Dr. Hearn and colleagues at University of Michigan have also developed a clinical trial for pts with advanced bladder cancer that combines immunotherapy with highly focused radiation (stereotactic body radiation therapy) to potentially synergistically enhance the immune response against cancer.

Dr. Hearn is also exploring novel techniques to improve the safety and efficacy of radiation therapy for lung cancer by incorporating advanced imaging, adaptive radiotherapy, and biologic information.

Areas of Interest

  • Prostate cancer
  • Bladder cancer
  • Lung cancer
  • Pediatric (childhood) malignancies

Clinical Interests

  • Genitourinary cancers (prostate, bladder, kidney/renal, urinary tract, testicular, and penile)
  • Bladder preservation therapy
  • Stereotactic body radiotherapy (SBRT; especially prostate SBRT and lung SBRT)
  • Thoracic tumors (lung, esophageal, thymic neoplasms, and mesothelioma)
  • Pediatric (childhood) malignancies
  • Conventional radiation therapy
  • Intensity modulated radiation therapy (IMRT)
  • Image-guided radiation therapy (IGRT)

Honors & Awards

2018    Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award
2017    Top Ten Clinical Research Achievement Award (national competition)
2015    U.S. Department of Defense Award: Prostate Cancer Research Program
2015    Prostate Cancer Foundation Challenge Award
2015    Conquer Cancer Foundation of ASCO Merit Award
2015    RSNA Roentgen Research Award
2013    Jerrold P. Saxton Award for Clinical Excellence
2004    Beta Beta Beta National Biological Honor Society
2004    Blue Key National Honor Society
2004    Delta Epsilon Sigma National Honor Society
2003    Alpha Lambda Delta National Honor Society
2002-2006  Dr. & Mrs. Mario J. Campagna Scholarship
2002-2006  Hopkin Jenkins Scholarship
2002-2006  Robert C. Byrd Honors Scholarship
2002-2006  Siegert Scholarship
2002-2006  Simon Benson Foundation Scholarship
2002-2006  University of Michigan President’s Scholarship

Credentials

  • MD, Harvard Medical School, 2010
  • Medical License: State of Michigan
  • Board Certification: Radiation Oncology

Grants

  • (PI: Hearn), 2016-2020, Bayer Corporation through a consortium with Hoosier Cancer Research Network: Androgen Deprivation Therapy with or without Radium-223 Dichloride in Patients with Newly Diagnosed Metastatic Prostate Cancer with Bone Metastases.
  • (PI: Hearn), 2015-2019, United States Department of Defense Physician Training Award: Germline variation in HSD3B1 as a novel biomarker in prostate cancer, Role: Co-Investigator.

Published Articles via PubMed

Published Articles or Reviews

  1. Tobalske BW, Hearn JWD, Warrick DR.: Aerodynamics of Intermittent Bounds in Flying Birds Experiments in Fluids 46(5): 963-973, 2009.
  2. Hearn JWD, Videtic GMM, Djemil T, Stephans KL.: Salvage Stereotactic Body Radiotherapy (SBRT) for Local Failure after Primary Lung SBRT International Journal of Radiation Oncology, Biology, Physics 90(2): 402-406, 2014. PM25017480
  3. Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang K-H, Carlson R, Rangel L, Reagan R, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, and Sharifi N: HSD3B1 and Resistance to Androgen-Deprivation Therapy in Prostate Cancer: A Retrospective, Multicohort Study Lancet Oncology 17(10): 1435-1444, 2016. PMC5135009
  4. Spratt D, Jackson W, Abugharib A, Tomlins S, Dess R, Soni P, Lee J, Zhao S, Cole A, Zumsteg Z, Sandler H, Hamstra D, Hearn JWD, Palapattu G, Mehra R, Morgan T, and Feng F: Independent Validation of the Prognostic Capacity of the ISUP Prostate Cancer Grade Grouping System for Radiation Treated Patients with Long-term Follow-up Prostate Cancer and Prostatic Diseases 19(3): 292-7, 2016. PMID 27215611
  5. Dess R, Sun Y, Matuszak M, Sun G, Soni P, Bazza L, Murthy V, Hearn JWD, Kong F, Kalemkerian G, Hayman J, Ten Haken R, Lawrence T, Schipper M, Jolly S.: Cardiac Events after Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small Cell Lung Cancer Journal of Clinical Oncology 35(13): 1395-1402, 2017. PMC5455464
  6. Jackson WC, Desai N, Abugharib A,Tumati V, Dess R, Lee J, Zhao Z, Soliman M, Folkert, M, Laine A, Hannan R, Zumsteg Z, Sandler H, Hamstra D, Montgomery J, Miller D, Kozminski M, Hollenbeck B, Hearn JWD, Palapattu G, Tomlins S, Mehra R, Morgan T, Feng F, Spratt D.: Anatomic Patterns of Recurrence Following Biochemical Relapse after Post-Prostatectomy Salvage Radiation Therapy: A Multi- Institutional Study BJU International 120(3): 351-357, 2017. 28139024
  7. Sun Y, Hawkins PG, Bi N, Tewari M, Hearn JWD, Hayman JA, Kalemkerian GP, Lawrence TS, Ten-Haken RK, Matuszak MM, Kong FM, Jolly S, Schipper MJ: Serum microRNA Signature Predicts Response to High-dose Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer International Journal of Radiation Oncology, Biology, Physics 100(Number 1): 107-114, 2017. PM29051037 /PMC5736451
  8. Hawkins PG, Boonstra PS, Hobson ST, Hearn JWD, Hayman JA, Ten Haken RK, Matuszak MM, Stanton P, Kalemkerian GP, Ramnath N, Lawrence TS, Schipper MJ, Kong (Spring) FM, Jolly S.: Radiationinduced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship Radiotherapy and Oncology 125 (2017): 66-72, 2017. PMID: 28947099
  9. Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, Palapattu GS, Schipper M, Feng FY, Morgan TM, Desai NB, Spratt DE.: Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival European Urology [Epub ahead of print]: pii: S0302-2838(17)31070-9. doi:10.1016/j.eururo.2017.12.023, 2018. PMID: 29306514
  10. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JWD, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA.: Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features JAMA Oncology [Epub ahead of print]: e175230. doi: 10.1001/jamaoncol.2017.5230, 2018. PMID: 29372236
  11. Litzenberg DW, Muenz DG, Archer PG, Jackson WC, Hamstra DA, Hearn JWD, Schipper MJ, Spratt DE: Changes in Prostate Orientation Due to Removal of a Foley Catheter Medical Physics. 45(4): 1369-1378, 2018. PMID 29474748
  12. Piert M, Shankar PR, Montgomery J, Kunju LP, Rogers V, Siddiqui J, Rajendiran T, Hearn JWD, George A, Shao X, Davenport MS.: Accuracy of tumor segmentation from multi-parametric prostate MRI and 18Fcholine PET/CT for focal prostate cancer therapy applications EJNMMI Res 8(1): 23, 2018. PMC5869349
  13. Hearn JWD, Xie W, Nakabayashi M, Almassi N, Reichard CA, Pomerantz M, Kantoff PW, Sharifi N: Association of HSD3B1 Genotype with Response to Androgen-Deprivation Therapy for Biochemical Recurrence after Radiotherapy for Localized Prostate Cancer JAMA Oncol 4(4): 558-562, 2018. PMC5933377
  14. Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw S, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD.: Multi-Institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Post-Prostatectomy Salvage Radiotherapy for Prostate Cancer European Urology. 2018 Jul; 74(1):99-106. doi: 10.1016/j.eururo.2017.10.009. Epub 2017 Nov 9.. (In Press) PMID: 29128208
  15. Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumstmeg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE: Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure European Urology. (In Press)
  16. Christensen RE, Nause-Osthoff RC, Waldman JC, Spratt DE, Hearn, JWD: Adverse Events in Radiation Oncology: A Case Series from Wake Up Safe, the Pediatric Anesthesia Quality Improvement Initiative Pediatric Anesthesia. (In Press) 30580487
  17. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Hearn JWD, Mehra R, Morgan TM, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE.: Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies International Journal of Radiation Oncology, Biology, Physics. (In Press)
Locations

1500 E Medical Center Dr
Ann Arbor, MI 48109-5010

734-936-4320